Is there any difference between endometrial hyperplasia and endometrial carcinoma in terms of expression of TRPM2 and TRPM7 ion channels?

dc.contributor.authorYalcin, Emre
dc.contributor.authorPala, Sehmus
dc.contributor.authorAtilgan, Remzi
dc.contributor.authorKuloglu, Tuncay
dc.contributor.authorOnalan, Ebru
dc.contributor.authorArtas, Gokhan
dc.contributor.authorBuran, Ilay
dc.date.accessioned2026-08-12T17:18:00Z
dc.date.issued2019
dc.departmentFırat Üniversitesi
dc.description.abstractBackground/aim: This study compared TRPM2 and TRPM7 ion channel gene expression and irnmunohistochemical staining in endometrial hyperplasia and endometrium adenocarcinoma. Materials and methods: Sections were taken from paraffin blocks of 120 patients who were divided into 6 groups as follows: G1 (n = 20), proliferative endometrium (PE); G2 (n = 20), EH without atypia; G3 (n = 20), EH with atypia; G4 (n = 20), stage 1A, grade 1 EC; G5 (n = 20), stage 1A, grade 2 EC; and G6 (n = 20), stage 1A, grade 3 EC. TRPM2 and TRPM7 genes were analyzed with qRT-PCR in paraffin-embedded tissue samples. Under light microscopy, TRPM2 and TRPM7 immunostaining scores of the samples taken from polylysine slides were evaluated. Results: Compared to G1, TRPM2 mRNA gene expression was significantly downregulated in G3 and G5. TRPM2 immunoreactivity scores were similar in all groups. TRPM7 mRNA gene expression was significantly downregulated in G2, G3, and G6 when compared to G1. TRPM7 immunoreactivity scores were similar in G1, G2, and G3, but significantly decreased in G4, G5, and G6. Conclusion: Reduction in TRPM7 ion channel activity may be a progression marker for endometrial hyperplasia regardless of the atypical criteria.
dc.description.sponsorshipScientific Research Grants Unit of Firat University [TF.17.13]
dc.description.sponsorshipThis study was funded by Scientific Research Grants Unit of Firat University (grant number: TF.17.13).
dc.identifier.doi10.3906/sag-1810-176
dc.identifier.endpage660
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue2
dc.identifier.orcid0000-0001-9874-3838
dc.identifier.pmid30997980
dc.identifier.scopus2-s2.0-85065048954
dc.identifier.scopusqualityQ2
dc.identifier.startpage653
dc.identifier.trdizinid336082
dc.identifier.urihttps://doi.org/10.3906/sag-1810-176
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/336082
dc.identifier.urihttps://hdl.handle.net/11508/52871
dc.identifier.volume49
dc.identifier.wosWOS:000465264700030
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTubitak Scientific & Technological Research Council Turkey
dc.relation.ispartofTurkish Journal of Medical Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260511
dc.subjectTRPM2
dc.subjectTRPM7
dc.subjectendometrial hyperplasia
dc.subjectendometrioid adenocarcinoma
dc.titleIs there any difference between endometrial hyperplasia and endometrial carcinoma in terms of expression of TRPM2 and TRPM7 ion channels?
dc.typeArticle

Dosyalar